ELSEVIER

Blood 142 (2023) 1032–1036

The 65th ASH Annual Meeting Abstracts

ORAL ABSTRACTS

705.CELLULAR IMMUNOTHERAPIES: LATE PHASE AND COMMERCIALLY AVAILABLE THERAPIES

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Jay Y. Spiegel, MDFRCPC[1], Michael D. Jain, MD PhD[2], Loretta J. Nastoupil, MD[3], John Tamaresis, PhD[4], Armin Ghobadi, MD[5], Yi Lin, MD PhD[6], Lazaros J. Lekakis[7], Patrick M. Reagan, MD[8], Olalekan O. Oluwole, MBBS[9], Joseph P McGuirk, DO[10], Abhinav Deol, MD[11], Kathleen Dorritie, MD[12], Alison R Sehgal, MD[12], Andre Goy, MD[13], Brian T. Hill, MD PhD[14], Charalambos Andreadis, MD[15], Javier L. Munoz[16], Matthew L. Ulrickson, MD[17], Jason Westin, MD[18], Julio C. Chavez, MD[19], Dilan A Patel[20], Miriam T. Jacobs, MD[21], Radhika Bansal, MBBS[6], N. Nora Bennani, MD[22], Vivek Patel, MD[9], Aaron P. Rapoport, MD[23], Julie M. Vose, MD MBA[24], David B. Miklos, MD PhD[25], Sattva S. Neelapu, MD[26], Frederick L. Locke, MD[2], Matthew A Lunning, DO, FACP[27], Saurabh Dahiya[25]

[1] Miller School of Medicine, University of Miami, Miami, FL
[2] Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
[3] MD Anderson Cancer Center, Houston, TX
[4] Department of Biomedical Data Science, Stanford University, Stanford, CA
[5] Division of Oncology, Washington University School of Medicine, Saint Louis, MO
[6] Mayo Clinic Cancer Center, Rochester, MN
[7] Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL
[8] Wilmot Cancer Institute, University of Rochester Medical Center, Fairport, NY
[9] Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN
[10] University of Kansas Medical Center, Westwood, KS
[11] Karmanos Cancer Institute/ Department of Oncology, Wayne State University, Detroit, MI
[12] UPMC Hillman Cancer Center, Pittsburgh, PA
[13] Lymphoma Division, John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ
[14] Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
[15] Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA
[16] Department of Hematology, Mayo Clinic, Phoenix, AZ
[17] Banner MD Anderson Cancer Center, Gilbert, AZ
[18] Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, Houston, TX
[19] Moffitt Cancer Center, Tampa, FL
[20] Washington University School of Medicine, Saint Louis, MO
[21] Medstar Georgetown University Hospital, Washington, DC
[22] Division of Hematology, Mayo Clinic, Rochester, MN
[23] University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
[24] Fred and Pamela Buffett Cancer Center/Division of Hematology and Oncology/Department of Internal Medicine, Univeristy of Nebraska, Omaha, NE
[25] Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Palo Alto, CA
[26] Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
[27] Fred and Pamela Buffett Cancer Center/Division of Hematology and Oncology/Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Introduction

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 Chimeric Antigen Receptor (CAR) T-cell therapy that induces durable responses in patients with relapsed or refractory large B-cell lymphoma. At a median of 63.1 months follow-up on the ZUMA-1 trial, median overall survival (OS) was 25.8 months with 5-year OS and PFS (progression-free survival) estimates of 42.6% (95% CI, 32.8-51.9) and 31.8% (95% CI, 22.9-41.1), respectively (Neelapu, Blood 2023). We previously reported outcomes of axi-cel patients treated with standard of care therapy, including 42% who did not meet eligibility criteria for ZUMA-1 based

on co-morbidities (Nastoupil, JCO 2020). Here we report results from this cohort at a median follow up of 58 months, as well as late outcomes of interest.

Results

The US Lymphoma CAR-T Consortium is comprised of 17 US academic centers who contributed data independent of the manufacturer. Two hundred and ninety-eight patients underwent leukapheresis with intent to manufacture standard of care axi-cel (n=298) as of September 30, 2018. In infused patients (n=275), OS and PFS were calculated from date of infusion.

After a median follow-up of 58 months, median OS was 34.9 months (95% CI 23.4 - 44.8) with the OS at 3, 4, and 5 years of 49.1% (95% CI 42.9 - 54.9%), 43% (95% CI 36.8 - 48.9%), and 40.3% (95% CI 34.2 - 46.4%), respectively. The median PFS was 8.7 months (95% CI 5.87 - 16.6) and the 3-,4-, and 5- year PFS were 36.1% (95% CI 30.4 - 41.8%), 30.7 (95% CI 25.2 - 36.4%), and 28.5% (95% CI 23 - 34.2%), respectively. Results of multi-variable modeling were similar to our prior analysis: male sex (HR 1.56, 95% CI 1.08 - 2.27, p =0.02); LDH above the upper limit of normal (HR 1.6, 95% CI 1.12 - 2.30, p = 0.01); ECOG status of 2-4 (HR 2.02, 95% CI 1.33 - 3.07, p = <0.001); and elevated bilirubin > 1.5 (HR 5.68, 95% CI 2.21 - 14.6, p = <0.001) were associated with decreased OS. Factors associated with decreased PFS included male sex (HR 1.68, 95% CI 1.20 - 2.37, p = 0.003), LDH above the upper limit of normal (HR 1.82, 95% CI 1.31 - 2.53, p = <0.001), ECOG status of 2-4 (HR 1.93, 95% CI 1.30 - 2.86, p = 0.001), elevated bilirubin (HR 3.68, 95% CI 1.45 - 9.37, p = 0.006) and receipt of 3 or more prior lines of therapy (HR 1.49, 95% CI 1.03 - 2.13, p = 0.032).

We also assessed events of interest including late PFS events and causes of non-relapse mortality (NRM). One hundred and ninety-one PFS events occurred after axi-cel infusion during the follow-up period, 151 due to lymphoma progression and 40 NRM. In the first 12 months post infusion, 131 progression events occurred,13 between 1 and 2 years post infusion, and 7 relapses after 2 years with the latest occurring 46.4 months after infusion. Thirteen NRM events occurred in the 1st year post infusion, 6 between 1- and 2-years post infusion and 21 occurring later than 2 years after infusion. Of the 40 NRM events, 21 were secondary to infection including fungal infections (n = 3, 2 candidemia, 1 candidemia and pneumocystis jiroveci pneumonia), JC encephalitis (n=1) and COVID-19 (n = 2). Nine deaths were attributed to secondary malignancy. Other causes of NRM included cerebral edema (n=1), HLH (n=1), intracranial hemorrhage (n=1), suicide (n=1), and unknown (n=6). The 5-year cumulative risk of relapse was 55.2% and the 5-year risk of non-relapse mortality was 16.2%.

Excluding non-melanoma skin cancers, twenty-three of 275 (8%) patients were diagnosed with subsequent malignancy after axi-cel treatment: 14/275 (5%) patients were diagnosed with myeloid malignancies (MDS (n=11), AML (n=2), CMML (n=1)); other malignancies included anal squamous cell carcinoma (ca) (n=1); histiocytic sarcoma (n=1); prostate ca (n=1); endometrial ca (n=1); lung ca (n=1); merkel cell ca (n = 1), mesothelioma (n=1), B-ALL (n = 1), and AITL (n=1).

Conclusion

This multi-center retrospective study showed similar 5-year results to the ZUMA-1 trial with a 5-year PFS and OS of 28.5% and 40.3%, despite including patients who did not meet ZUMA-1 eligibility criteria based on comorbidities. Non-relapse mortality was primarily due to infection and secondary malignancy. This report supports the curative potential of axi-cel but highlights the competing risk of NRM in this high-risk patient population.

Disclosures Spiegel: *Kite Gilead:* Consultancy; *ImmPact Bio:* Consultancy. **Jain:** *Myeloid Therapeutics:* Consultancy, Honoraria; *Kite/Gilead:* Consultancy, Honoraria, Research Funding; *Loxo@Lilly:* Research Funding; *Incyte:* Research Funding. **Nastoupil:** *Gilead Sciences/Kite Pharma:* Honoraria, Research Funding; *AstraZeneca:* Honoraria; *Regeneron:* Honoraria; *Genentech, Inc., Genmab, Gilead/Kite, Janssen, Merck, Novartis, Takeda:* Honoraria, Research Funding; *Daiichi Sankyo:* Honoraria, Research Funding; *DeNovo:* Honoraria; *Caribou Biosciences:* Honoraria, Research Funding; *Bristol Myers Squibb/Celgene:* Honoraria, Research Funding; *ADC Therapeutics:* Honoraria; *AbbVie:* Honoraria. **Ghobadi:** *Kite/Gilead:* Consultancy, Honoraria, Research Funding; *Wugen Inc:* Consultancy; *CRISPR Therapeutics:* Consultancy; *Genentech, Inc.:* Research Funding; *BMS:* Consultancy; *Atara:* Consultancy; *Amgen:* Consultancy, Research Funding. **Reagan:** *Caribou biosciences:* Consultancy; *Genentech:* Research Funding; *Seagen:* Research Funding; *Kite, a Gilead Company:* Consultancy, Other: speaker. **Oluwole:** *Allogene:* Research Funding; *Pfizer:* Consultancy, Honoraria, Research Funding; *AbbVie:* Consultancy; *ADC:* Consultancy, Speakers Bureau; *Cargo:* Consultancy; *Caribou:* Consultancy; *Epizyme:* Consultancy; *Kite, a Gilead Company/ Gilead:* Consultancy, Research Funding; *Nektar:* Consultancy; *Novartis:* Consultancy; *TGR:* Consultancy; *Daiichi Sankyo:* Research Funding; *Gilead:* Consultancy, Honoraria. **McGuirk:** *Kite:* Consultancy, Research Funding; *Magenta Therapeutics:* Consultancy; *Bellicum Pharmaceuticals:* Research Funding; *Astellas Pharma:* Research Funding; *Fresenius Biotech:* Research Funding; *Novartis:* Research Funding; *EcoR1 Capital:* Consultancy; *Juno Therapeutics:* Consultancy; *Allovir:* Consultancy, Research Funding; *Gamida Cell:* Research Funding; *Pluristem Therapeutics:* Research Funding. **Dorritie:** *BMS:* Membership on an entity's Board of Directors or advisory committees, Research Funding; *Genmab:* Research Funding; *Hoffman-LaRoche:* Research Funding; *Janssen:* Research Funding; *Curio and Dava Oncology:* Honoraria; *Kite, a Gilead Company:* Research Funding; *Genentech:* Research Funding. **Sehgal:** *Bristol Myers Squibb:* Research Funding; *Chimagen:* Research Funding; *Cytoagents:* Research Funding; *Kite/Gilead:* Research Funding; *PeerView Live:* Speakers Bureau; *OncLive:* Speakers Bureau. **Goy:** *Medscape:* Consultancy; *Michael J. Hennessey:* Consultancy, Honoraria; *Physicians Education Resource, LLC:* Consultancy, Honoraria, Other: travel, accommodations, and expenses; *Acerta:* Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; *Novartis:* Consultancy, Honoraria; *Infinity:* Research Funding; *Xcenda:* Consultancy, Honoraria; *Seagen:* Research Funding; *Verastem:* Research Funding; *AbbVie/ Pharmacyclics LLC:* Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Steering Committee, Research Funding; *Janssen:* Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Steering Committee, Research

Funding; *AstraZeneca:* Membership on an entity's Board of Directors or advisory committees, Other: Steering Committee, Research Funding; *Clinical Advances in Hematology & Oncology:* Consultancy; *Kite, a Gilead Company:* Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; *Karyopharm:* Research Funding; *Genentech:* Research Funding; *Bristol Myers Squibb/Celgene:* Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding; *Constellation:* Research Funding; *Hoffman la Roche:* Consultancy, Honoraria, Research Funding; *Vincerx:* Honoraria, Membership on an entity's Board of Directors or advisory committees, Other; *OMI:* Current Employment; *MorphoSys:* Research Funding; *Pharmacyclics LLC, an AbbVie Company:* Other: Steering Committee, Research Funding; *Resilience:* Current holder of *stock options* in a privately-held company; *Alloplex:* Current holder of *stock options* in a privately-held company, Honoraria, Membership on an entity's Board of Directors or advisory committees; *Genomics Testing Cooperative LLC:* Current holder of *stock options* in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Other: Leadership Role; *COTA Healthcare:* Current holder of *stock options* in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Other: Leadership Role; *Regional Cancer Care Associates, OMI:* Current Employment, Research Funding; *OncLive Peer Exchange:* Honoraria; *Practice Update Oncology:* Consultancy, Honoraria. **Hill:** *Pharmacyclics:* Consultancy, Other: Advisory board, Research Funding; *Kite, a Gilead Company:* Consultancy, Honoraria, Other: travel support, Research Funding; *Genentech:* Consultancy, Other: Advisory board, Research Funding; *Bristol Myers Squibb:* Consultancy; *BeiGene:* Consultancy; *AstraZeneca:* Consultancy; *AbbVie:* Consultancy, Other: Advisory board, Research Funding; *Incyte:* Consultancy; *Gilead:* Other: Advisory board. **Andreadis:** *Lilly:* Research Funding; *Roche:* Research Funding; *Astra Zeneca:* Honoraria; *Epizyme:* Honoraria; *Gilead:* Honoraria; *BMS:* Honoraria, Research Funding; *Novartis:* Research Funding; *pharmacyclics:* Honoraria; *Merck:* Research Funding. **Munoz:** *Beigene:* Consultancy, Research Funding, Speakers Bureau; *Acrotech/Aurobindo:* Consultancy, Speakers Bureau; *Pharmacyclics/ Janssen:* Consultancy, Research Funding, Speakers Bureau; *Alexion:* Consultancy; *MEI:* Consultancy; *TG Therapeutics:* Consultancy; *OncView:* Honoraria; *Kite, a Gilead Company:* Consultancy, Research Funding, Speakers Bureau; *Pfizer:* Consultancy; *Merck:* Research Funding; *Seattle Genetics:* Consultancy, Honoraria, Research Funding, Speakers Bureau; *Kyowa:* Honoraria, Speakers Bureau; *ADC Therapeutics:* Consultancy; *Celgene/ Bristol-Myers Squibb:* Consultancy, Speakers Bureau; *Verastem:* Consultancy, Speakers Bureau; *AstraZeneca:* Consultancy, Speakers Bureau; *Physicians' Education Resource:* Honoraria; *Lilly/Loxo:* Consultancy; *Epizyme:* Consultancy; *Curio:* Honoraria; *Karyopharm:* Consultancy; *Genmab:* Consultancy; *Morphosys/Incyte:* Consultancy; *Celgene:* Research Funding; *Targeted Oncology:* Honoraria; *Genentech/Roche:* Consultancy, Research Funding, Speakers Bureau; *Incyte:* Research Funding; *Portola:* Research Funding; *Millennium:* Research Funding; *Bayer:* Consultancy, Research Funding, Speakers Bureau; *Pharmacyclics/Abbvie:* Consultancy, Research Funding. **Ulrickson:** *Gilead Sciences:* Consultancy; *Stemline:* Consultancy. **Westin:** *Abbvie:* Consultancy; *Kite/Gilead:* Consultancy, Research Funding; *AstraZeneca:* Consultancy, Research Funding; *Genentech:* Consultancy, Research Funding; *Morphosys/Incyte:* Consultancy, Research Funding; *SeaGen:* Consultancy; *MonteRosa:* Consultancy; *Kymera:* Research Funding; *ADC Therapeutics:* Consultancy, Research Funding; *Calithera:* Research Funding; *Nurix:* Consultancy; *Novartis:* Consultancy, Research Funding; *BMS:* Consultancy, Research Funding. **Chavez:** *Eli Lilly:* Speakers Bureau; *BeiGene:* Speakers Bureau; *Novartis:* Consultancy; *Kite, a Gilead Company:* Consultancy; *GenMab:* Consultancy; *Genentech:* Consultancy; *Bristol Myers Squibb:* Consultancy; *AstraZeneca:* Consultancy, Research Funding; *AdiCet:* Consultancy; *Janssen:* Research Funding; *Merck:* Research Funding; *ADC Therapeutics:* Consultancy, Research Funding. **Bennani:** *Secura Bio:* Other: Advisory board; No personal compensation; *Affimed:* Other: Advisory board; No personal compensation; *Astellas Pharma:* Other: Advisory board; No personal compensation; *Acrotech:* Other: Advisory board; No personal compensation; *Acrotech:* Other: Scientific Advisory Committee, No personal compensation ; *Kymera:* Other: Advisory board; No personal compensation. **Vose:** *Eli Lilly and Company; Epizyme, Kite, Loxo, Novartis:* Research Funding; *AbbVie, MEI Pharma:* Consultancy. **Miklos:** *MorphoSys:* Consultancy, Honoraria; *Genentech:* Consultancy, Honoraria; *Amgen:* Consultancy, Honoraria; *Fate Therapeutics:* Research Funding; *2Seventy Bio:* Research Funding; *Allogene:* Research Funding; *Adicet:* Research Funding; *Miltenyi:* Consultancy, Research Funding; *Bristol-Myers Squibb:* Consultancy; *Kite, a Gilead Company:* Consultancy, Research Funding; *NA:* Patents & Royalties: cGVHD patent holder for Ibrutinib as cGVHD therapy but no compensation; *A2 Biotherapeutics:* Consultancy, Current holder of *stock options* in a privately-held company, Honoraria; *Celgene:* Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; *Novartis:* Consultancy, Honoraria; *Legend Biotech:* Consultancy, Honoraria; *Mustang Bio:* Consultancy, Honoraria; *Navan Technologies:* Consultancy, Current holder of *stock options* in a privately-held company, Honoraria; *Gilead Sciences:* Consultancy, Honoraria; *Pharmacyclics:* Consultancy, Honoraria; *Umoja:* Consultancy, Honoraria; *Juno Therapeutics:* Consultancy, Honoraria, Patents & Royalties: rights to royalties from Fred Hutch for patents licensed to Juno, Research Funding; *Incyte:* Consultancy, Honoraria; *Adaptive Biotechnologies:* Consultancy; *Janssen:* Consultancy, Honoraria, Other: Travel support; *Bioline Rx:* Membership on an entity's Board of Directors or advisory committees. **Neelapu:** *Precision Biosciences:* Research Funding; *Carsgen:* Consultancy; *Kite, A Gilead Company:* Consultancy, Other: Advisory Board Member, Research Funding; *Merck:* Consultancy, Other: Advisory Board Member; *Sellas Life Sciences:* Consultancy, Other: Advisory board member; *Orna Therapeutics:* Consultancy, Other: Advisory board member; *Takeda:* Consultancy, Other: Advisory board member; *Bluebird Bio:* Consultancy, Other: Advisory board member; *Morphosys:* Consultancy, Other: Advisory board member; *Janssen:* Consultancy, Other: Advisory board member; *Chimagen:* Consultancy, Other: Advisory board member; *Adicet Bio:* Consultancy, Other: Advisory board member, Research Funding; *Bristol Myers Squibb:* Consultancy, Other: Advisory Board Member, Research Funding; *Allogene:* Consultancy, Other: Advisory board member, Research Funding; *Incyte:* Consultancy, Other: Advisory board member; *Immunoadoptive Cell Therapy Private Limited:* Consultancy, Other: Scientific Advisory Board; *Athenex:* Consultancy, Other: Advisory board member; *Synthekine:* Consultancy, Other: Advisory board member; *Fosun Kite:* Consul-

tancy, Other: Advisory board member; *Longbow Immunotherapy:* Current holder of *stock options* in a privately-held company; *Caribou:* Consultancy, Other: Advisory board member; *Astellas Pharma:* Consultancy, Other: Advisory board member; *Sana Biotechnology:* Consultancy, Other: Advisory board member, Research Funding; *N/A:* Patents & Royalties: Related to cell therapy and the safety switch described (intellectual property). **Locke:** *National Cancer Institute:* Other; *Iovance:* Consultancy, Membership on an entity's Board of Directors or advisory committees; *Bluebird Bio:* Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Institutional; *Umoja:* Consultancy, Membership on an entity's Board of Directors or advisory committees; *Takeda:* Consultancy, Membership on an entity's Board of Directors or advisory committees; *Imedex:* Other; *CERo Therapeutics:* Other: (Institutional); *Leukemia and Lymphoma Society:* Other; *Kite, a Gilead Company:* Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Institutional , Research Funding; *Bristol Myers Squibb/ Celgene:* Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Institutional , Research Funding; *Legend Biotech:* Consultancy, Membership on an entity's Board of Directors or advisory committees; *Janssen:* Consultancy, Membership on an entity's Board of Directors or advisory committees; *ASH:* Other: Travel Support; *BioPharma Communications CARE Education:* Other: Institutional; *Cellular Medicine Group:* Consultancy; *Cowen:* Consultancy; *Emerging Therapy Solutions:* Consultancy, Other; *Sana:* Consultancy, Membership on an entity's Board of Directors or advisory committees; *GammaDelta Therapeutics:* Consultancy; *EcoR1:* Consultancy; *Pfizer:* Membership on an entity's Board of Directors or advisory committees; *Aptitude Health:* Other: Travel Support; *Society for Immunotherapy of Cancer:* Other; *Clinical Care Options Oncology:* Other; *Calibr:* Consultancy; *Daiichi Sankyo:* Consultancy; *Caribou:* Consultancy; *Wugen:* Consultancy, Membership on an entity's Board of Directors or advisory committees; *Amgen:* Consultancy, Membership on an entity's Board of Directors or advisory committees; *Allogene:* Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Institutional ; *Novartis:* Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Institutional , Research Funding; *Gerson Lehrman Group (GLG):* Consultancy; *A2 Biotherapeutics:* Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support. **Lunning:** *InstilBio:* Consultancy, Honoraria; *GenMab:* Consultancy, Honoraria; *Genentech:* Consultancy, Honoraria; *Fate Therapeutics:* Consultancy, Honoraria; *EUSA:* Consultancy, Honoraria; *Daiichi Sankyo:* Consultancy, Honoraria; *CRISPR:* Consultancy, Honoraria; *Caribou:* Consultancy, Honoraria; *BMS:* Consultancy, Honoraria, Research Funding; *Astellas:* Consultancy, Honoraria; *Astra Zeneca:* Consultancy, Honoraria; *ADC Therapeutics:* Consultancy, Honoraria; *Acrotech:* Consultancy, Honoraria; *AbbVie:* Consultancy, Honoraria; *Ipsen:* Consultancy, Honoraria; *Janssen:* Consultancy, Honoraria; *Kite:* Consultancy, Honoraria; *Loxo:* Consultancy, Honoraria; *Miltenyi:* Consultancy, Honoraria; *Morphosys:* Consultancy, Honoraria; *Novartis:* Consultancy, Honoraria; *Nurix:* Consultancy, Honoraria; *Pharmacyclics:* Consultancy, Honoraria; *Regeneron:* Consultancy, Honoraria; *Sanofi:* Consultancy, Honoraria; *SeaGen:* Consultancy, Honoraria; *Takeda:* Consultancy, Honoraria; *TG Therapeutics:* Consultancy, Honoraria; *Curis:* Research Funding. **Dahiya:** *Adaptive Biotechnologies:* Consultancy; *Kite, a Gilead Company:* Consultancy, Research Funding; *Bristol Myers Squibb:* Consultancy; *Incyte:* Consultancy.

https://doi.org/10.1182/blood-2023-179868





Figure 1: (A) OS and (B) PFS for the infused cohort of 275 patients

Figure 1